- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Bruce Quinn Describes How Europe and the US Regulate Diagnostic Tests Differently
While the FDA could regulate diagnostic tests the way they are in Europe-through simple verification that the test is accurate-the FDA has not chosen to do that and comes closer to requiring clinical utility, explained Bruce Quinn, MD, PhD, senior director at FaegreBD Consulting.
While the FDA could regulate diagnostic tests the way they are in Europe—through simple verification that the test is accurate—the FDA has not chosen to do that and comes closer to requiring clinical utility, explained Bruce Quinn, MD, PhD, senior director at FaegreBD Consulting.
Transcript (slightly modified)
What shoud the FDA be focusing on more when it comes to diagnostic testing: clinical utility or clinical validity?
It depends what paradigm the FDA wants to use. The model that's used in Europe is simply to verify that the test is accurate. And for that reason a lot of kits are CE marked in Europe, they're used in the United Kingdom, they're used in Canada long before they're available in the United States, because they've simply proved that the test is accurate: it can detect these 5 mutations or those 7 mutations.
Although the FDA could do that, it has paired the approval with the actual drug activity for most combination diagnostics. So if a gene is known to be paired with a drug, they won't let you just produce an accurate genetic test by itself. The FDA requires it to be closely correlated with the drug outcome. I think we would solve a lot of problems if for those genetic tests we simply asked that the test be accurate, which is the standard that's used in Europe.
One of the issues for the FDA that brings it much closer to clinical utility, even if they don't use the word, is if they're looking at risk and benefit. And once you define the risk as being certain bad outcomes or certain disadvantages, you have to define the benefit to counterbalance that, and the benefit is really a clinical utility. It's something that's beneficial to the patient.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
